Confidence+ in our support program
Dealing with hyperphosphatemia can be challenging for your patients with end stage renal disease (ESRD). And you can't be with them all the time. That's why we created the FOSRENOL On Track™ Support Program, a support program that reinforces your efforts and provides patients with materials designed to help them manage their condition.
Pay No More Than $5 per Rx*
*Up to $150 per monthly
Restrictions may apply.
Experience+ with FOSRENOL
- Available for more than 9 years1
- Over 5200 patients studied in completed clinical trials2
- Approved in 20041
Flexible Dosing+ offers options for you and your patients
FOSRENOL tablets are available in multiple dosage strengths, which allows titration with 1 tablet per meal2
- Recommended starting daily dose is 1500 mg–one 500-mg tablet with or immediately after meals*
- Titrate as need with 500-mg, 750-mg, or 1000-mg tablets†
*Dosing based on 3 meals per day. Number of meals per day may vary. To Achieve certain doses, additional tables may be required.
†Dosing should be titrated every 2 to 3 weeks until an acceptable serum phosphorus level is reached. Monitor serum phosphorous levels as needed during dose titration and on a regular basis thereafter. Doses were generally titrated in increments of 750 mg/day. In clinical studies, most patients required a total daily dose of 1500-3000 mg to reduce serum phosphorus levels to <6.0 mg/dL.
To learn more about dosing with FOSRENOL go to FOSRENOL.com.
- FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).
Important Safety Information
- FOSRENOL is contraindicated in patients with bowel obstruction, ileus, and fecal impaction.
- Serious cases of gastrointestinal obstruction, ileus, and fecal impaction have been associated with lanthanum use, some requiring surgery or hospitalization. Risk factors include altered gastrointestinal anatomy, hypomotility disorders, and concomitant medications.
- Instruct patients to chew or crush the tablet completely to reduce the risk of serious adverse gastrointestinal events. Advise patients with poor dentition that they may crush tablets completely. Advise patients to take FOSRENOL with or immediately after meals.
- Patients with acute peptic ulcer, ulcerative colitis, Crohn’s disease, or bowel obstruction were not included in FOSRENOL clinical studies.
- FOSRENOL has radio-opaque properties and may give the appearance typical of an imaging agent during abdominal X-ray procedures.
- The most common adverse reactions seen with FOSRENOL in clinical trials included nausea, vomiting, diarrhea, and abdominal pain.
- There is potential for FOSRENOL to interact with:
These concomitant medications should be dosed separately from FOSRENOL to avoid drug interactions. See the Full Prescribing Information for dosing recommendations.
- compounds that bind to cationic antacids (ie, aluminum-, magnesium-, or calcium-based)
- oral quinolone antibiotics
- thyroid hormone replacement therapy
- FOSRENOL is Pregnancy Category C. FOSRENOL is not recommended for use during pregnancy. It is not known whether FOSRENOL is excreted in human milk. Use caution when prescribing FOSRENOL to a nursing woman.
- The safety and efficacy of FOSRENOL in pediatric patients have not been established. The use of FOSRENOL in this population is not recommended.
Please click here for Full Prescribing Information for FOSRENOL (lanthanum carbonate).